A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This research study is designed to look at the effects of the combination of vorinostat
(Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue. The
investigators will do this by comparing tissues from the original breast biopsy to tissues
obtained after taking vorinostat and tamoxifen for 2 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins